Can a simple blood thinner save teens from deadly clots?

NCT ID NCT06628778

Not yet recruiting Prevention Sponsor: Johns Hopkins All Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the blood thinner enoxaparin can prevent dangerous blood clots in teens who are critically ill in the intensive care unit. About 800 high-risk teens will receive either enoxaparin or a placebo. The goal is to see if the drug reduces clots without causing serious bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enoxaparin (a blood thinner)
What this could lead to: If it works, this could provide a proven way to prevent dangerous blood clots in hospitalized teens, reducing complications and saving lives.
What could go wrong: This is a first-of-its-kind trial in children, so results are uncertain. Enoxaparin also raises bleeding risk, which must be carefully balanced against any benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM (VTE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENOUS THROMBOEMBOLISM (VTE)

Contacts and locations

Locations

Johns Hopkins All Children"s Hospital

St. Petersburg, Florida, 33704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.